JP2012503666A - ベンダムスチン液体製剤 - Google Patents
ベンダムスチン液体製剤 Download PDFInfo
- Publication number
- JP2012503666A JP2012503666A JP2011529180A JP2011529180A JP2012503666A JP 2012503666 A JP2012503666 A JP 2012503666A JP 2011529180 A JP2011529180 A JP 2011529180A JP 2011529180 A JP2011529180 A JP 2011529180A JP 2012503666 A JP2012503666 A JP 2012503666A
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- bendamustine
- pharmaceutically acceptable
- polar protic
- protic solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 title claims abstract description 82
- 229960002707 bendamustine Drugs 0.000 title claims abstract description 80
- 239000012669 liquid formulation Substances 0.000 title abstract description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 239000003880 polar aprotic solvent Substances 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims description 150
- 238000009472 formulation Methods 0.000 claims description 134
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 62
- 239000003586 protic polar solvent Substances 0.000 claims description 35
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 21
- 238000004458 analytical method Methods 0.000 claims description 20
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical group CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 claims description 5
- 229920000858 Cyclodextrin Polymers 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 229940034982 antineoplastic agent Drugs 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 229920001515 polyalkylene glycol Polymers 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 150000003140 primary amides Chemical class 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 239000004067 bulking agent Substances 0.000 claims description 2
- 239000008139 complexing agent Substances 0.000 claims description 2
- 239000000539 dimer Substances 0.000 claims description 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 125000003158 alcohol group Chemical group 0.000 claims 4
- 239000003125 aqueous solvent Substances 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 3
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 3
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 3
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 238000007865 diluting Methods 0.000 claims 2
- 239000008354 sodium chloride injection Substances 0.000 claims 2
- 239000007972 injectable composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 25
- 229960001215 bendamustine hydrochloride Drugs 0.000 description 17
- 238000004128 high performance liquid chromatography Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000000523 sample Substances 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- -1 polybutylene Polymers 0.000 description 6
- 229940066958 treanda Drugs 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 241000282567 Macaca fascicularis Species 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 2
- GPYWLSZJZNELNN-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]-4-hydroxybutanoic acid Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(C(O)CCC(O)=O)=NC2=C1 GPYWLSZJZNELNN-UHFFFAOYSA-N 0.000 description 2
- XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 2
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- BPZIKXXNXMYQPN-UHFFFAOYSA-N 4-[6-[bis(2-chloroethyl)amino]-1h-benzimidazol-2-yl]butanoic acid Chemical compound C1=C(N(CCCl)CCCl)C=C2NC(CCCC(=O)O)=NC2=C1 BPZIKXXNXMYQPN-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000002105 relative biological effectiveness Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Abstract
【選択図】 図1
Description
ベンダムスチンの安定した液体製剤が発見され、本明細書で報告される。
1−メチル−2−ピロリドン(NMP)、1,3−ジメチル−2−イミダゾリジノン(DMI)、ジメチルアセトアミド(DMA)、ジメチルスルホキシド(DMSO)、アセトン、テトラヒドロフラン(THF)、ジメチルホルムアミド(DMF)、および炭酸プロピレン(PC)をはじめとする溶剤について平衡状態溶解度を測定した。ベンダムスチン塩酸塩の溶解度はまた、DMA中の25mg/mLナイアシンアミド、および66%DMA/34%プロピレングリコール(PG)中の25mg/mLナイアシンアミドの2種の溶液についても測定した。ベンダムスチン塩酸塩の飽和溶液は各溶剤または溶液について三連で作成し、Lab−Quake上で穏やかな混合および低剪断により室温で3日間混合した。各懸濁液のサンプルを微小遠心管に入れ、Eppendorf微量遠心機上で10,000rpmで5分間遠沈させた。上清を取り出して清潔なバイアルに入れた。50%:50%のNMPと0.1%トリフルオロ酢酸の水溶液であるサンプル溶剤で、各溶液を希釈した。ベンダムスチン塩酸塩のための逆相法を使用して、標準から計算した各サンプル濃度を判定した。分析は希釈サンプル調製の18時間以内に実施した。溶解度を下の表Iに列挙する。各値は3つのサンプルの平均である。
4匹の(18〜23時間)絶食させた薬剤未感作オスのカニクイザルに、3種の異なる製剤から調製したベンダムスチン塩酸塩の3mg/kg単一ボーラス静脈内用量を逐次投与した。本研究で評価した製剤は、次のとおりであった。1)TREANDA(ベンダムスチン塩酸塩およびマンニトールの凍結乾燥混合物;25mg(ベンダムスチン塩酸塩))バイアル;2)66%ジメチルアセトアミド(DMA)/34%プロピレングリコール(PG)(w/w)溶液(90mg(ベンダムスチン塩酸塩)/mL原液);および3)100%のDMA溶液(45mg(ベンダムスチン塩酸塩)/mL原液)。用量投与の直前に、ベンダムスチン塩酸塩の凍結乾燥粉末および原液を必要に応じて0.9%食塩水で戻し、または希釈して3mg/mlのベンダムスチン塩酸塩溶液を得た。得られた溶液を1.0mL/kgの固定容積で、伏在静脈を通じてボーラスとして投与した。逐次用量を隔てる、少なくとも7日間の休薬期間があった。3つの投与相全てにおいて、投与直前および投与後12時間内のあらかじめ選択された時点で、ベンダムスチンおよびその2種の活性循環代謝産物であるγ−ヒドロキシベンダムスチン(M3)およびN−des−メチルベンダムスチン(M4)の薬物動態学的プロファイリングのための血液サンプルを大腿静脈を通じて収集した。タンデム質量分光測定の検出(LC−MS/MS)付きの検証済み高速液体クロマトグラフィー法を使用して、次のように血漿サンプル中のベンダムスチン、M3およびM4濃度を測定した。アセトニトリルを用いてタンパク質沈殿によって、血漿からベンダムスチン、M3、およびM4の代謝産物を抽出した。抽出後、等分したサンプルトを1%ギ酸で酸性化し、カルボン酸鎖中に1個の炭素が付加しているベンダムスチンを内部基準として添加した。サンプルを蒸発させて乾燥し、残留物をアセトニトリル/水/ギ酸/ギ酸アンモニウム混合物に溶解した。サンプルをLC/MS/MS検出付きのHPLCシステムに注入して、アセトニトリル/水/ギ酸/ギ酸アンモニウムを移動相としてPhenomenex Synergi Max−RPカラムを使用し、無隔壁法を用いて薬物動態学的分析を実施した。
0.9%塩化ナトリウム(500mLバッグ)中の混和材料を高用量(360mgベンダムスチン塩酸塩)で調製し、Zorbax Bonus−RPカラムを使用して、93%:7%の水中0.1%トリフルオロ酢酸(移動相A)とアセトニトリル中0.1%トリフルオロ酢酸(移動相B)から、10%:90%の移動相A/移動相Bへの勾配でHPLCを使用して、最高8時間まで室温で純度を経時的に判定した。
Claims (62)
- ベンダムスチン、またはその薬学的に許容できる塩またはプロドラッグと、極性非プロトン性溶剤とを含んでなる液体医薬製剤。
- 前記極性非プロトン性溶剤が、1−メチル−2−ピロリドン、1,3−ジメチル−2−イミダゾリジノン、ジメチルアセトアミド、ジメチルスルホキシド、アセトン、テトラヒドロフラン、1,4−ジオキサン、アセトニトリル、ジメチルホルムアミド、炭酸プロピレン、またはそれらの混合物である、請求項1に記載の製剤。
- 前記極性非プロトン性溶剤がジメチルアセトアミド、ジメチルスルホキシド、またはそれらの混合物である、請求項1に記載の製剤。
- 非水性極性プロトン性溶剤をさらに含んでなる、請求項1に記載の製剤。
- 前記非水性極性プロトン性溶剤が、アルコール、ポリアルキレングリコール、アミド、またはそれらの混合物である、請求項4に記載の製剤。
- 前記非水性極性プロトン性溶剤がアルコールである、請求項4に記載の製剤。
- 前記アルコールがグリコールである、請求項6に記載の製剤。
- 前記グリコールが、エチレングリコール、プロピレングリコール、ブチレングリコール、またはそれらの混合物である、請求項7に記載の製剤。
- 前記アルコールがシクロデキストリンである、請求項6に記載の製剤。
- 前記シクロデキストリンがヒドロキシプロピル−β−シクロデキストリンである、請求項9に記載の製剤。
- 前記製剤が製剤の90容積%以下の非水性極性プロトン性溶剤を含んでなる、請求項4に記載の製剤。
- 前記製剤が製剤の約20容積%〜約85容積の非水性極性プロトン性溶剤を含んでなる、請求項4に記載の製剤。
- 前記製剤が製剤の約30容積%〜約70容積%の非水性極性プロトン性溶剤を含んでなる、請求項4に記載の製剤。
- 前記製剤が製剤の約80容積%の非水性極性プロトン性溶剤を含んでなる、請求項4に記載の製剤。
- 前記製剤が製剤の約67容積%の非水性極性プロトン性溶剤を含んでなる、請求項4に記載の製剤。
- 前記製剤が製剤の約34容積%の非水性極性プロトン性溶剤を含んでなる、請求項4に記載の製剤。
- 前記極性非プロトン性溶剤がジメチルアセトアミドであり、前記非水性極性プロトン性溶剤がプロピレングリコールである、請求項4に記載の製剤。
- 薬学的に許容できる抗酸化剤をさらに含んでなる、請求項1に記載の製剤。
- 約5mg/ml〜約200mg/mLのベンダムスチン、または薬学的に許容できるその塩を含んでなる、請求項1に記載の製剤。
- 約5mg/ml〜約120mg/mLのベンダムスチン、または薬学的に許容できるその塩を含んでなる、請求項1に記載の製剤。
- 少なくとも約5mg/mLのベンダムスチン、または薬学的に許容できるその塩を含んでなる、請求項1に記載の製剤。
- 少なくとも約40mg/mLのベンダムスチン、または薬学的に許容できるその塩を含んでなる、請求項1に記載の製剤。
- 少なくとも約60mg/mLのベンダムスチン、または薬学的に許容できるその塩を含んでなる、請求項1に記載の製剤。
- 少なくとも約80mg/mLのベンダムスチン、または薬学的に許容できるその塩を含んでなる、請求項1に記載の製剤。
- 少なくとも約100mg/mLのベンダムスチン、または薬学的に許容できるその塩を含んでなる、請求項1に記載の製剤。
- 少なくとも約200mg/mLのベンダムスチン、または薬学的に許容できるその塩を含んでなる、請求項1に記載の製剤。
- 前記製剤が約5℃で約30日間〜約365日間安定している、請求項1に記載の製剤。
- 前記製剤が約5℃で少なくとも約30日間安定している、請求項1に記載の製剤。
- 前記製剤が約5℃で少なくとも約90日間安定している、請求項1に記載の製剤。
- 前記製剤が約5℃で少なくとも約180日間安定している、請求項1に記載の製剤。
- 前記製剤の分析が、保存条件に曝露される前に存在した量の約90%以上のベンダムスチンを製剤が含有することを示唆する、請求項1に記載の製剤。
- 前記製剤の分析が、保存条件に曝露される前に存在した量の約95%以上のベンダムスチンを製剤が含有することを示唆する、請求項1に記載の製剤。
- 前記保存条件が約5℃で約30日間〜約365日である、請求項31および32のいずれか一項に記載の製剤。
- 前記保存条件が約5℃で少なくとも約30日間である、請求項31および32のいずれか一項に記載の製剤。
- 前記保存条件が約5℃で少なくとも約90日間である、請求項31および32のいずれか一項に記載の製剤。
- 前記保存条件が約5℃で少なくとも約180日間である、請求項31および32のいずれか一項に記載の製剤。
- 少なくとも1種の薬学的に許容できる賦形剤をさらに含んでなる、請求項1および4のいずれか一項に記載の製剤。
- 抗酸化剤、界面活性剤、脂質、増量剤、有機酸、親水性ポリマー、錯化剤、保存料、またはその組み合わせをさらに含んでなる、請求項1および4のいずれか一項に記載の製剤。
- 少なくとも1種の抗新生物薬をさらに含んでなる、請求項1および4のいずれか一項に記載の製剤。
- 前記製剤が1Lあたり10モル以下の非水性極性プロトン性溶剤を含んでなる、請求項4に記載の製剤。
- 前記製剤が1Lあたり約4〜約9.5モルの非水性極性プロトン性溶剤を含んでなる、請求項4に記載の製剤。
- 前記製剤が1Lあたり約9.1モルの非水性極性プロトン性溶剤を含んでなる、請求項4に記載の製剤。
- 前記製剤が1Lあたり約4.6モルの非水性極性プロトン性溶剤を含んでなる、請求項4に記載の製剤。
- 前記製剤が製剤の90容積%以下の非水性極性プロトン性溶剤を含んでなる、請求項4に記載の製剤。
- 約0.4%以下のHP1を含んでなる、請求項1および4のいずれか一項に記載の製剤。
- 約0.1%以下のHP1を含んでなる、請求項1および4のいずれか一項に記載の製剤。
- 約1.5%以下のDCEを含んでなる、請求項1および4のいずれか一項に記載の製剤。
- 約0.7%以下のBM1二量体を含んでなる、請求項1および4のいずれか一項に記載の製剤。
- 約1.5%以下のPG−1、PG−2、またはその組み合わせを含んでなる、請求項17に記載の製剤。
- ベンダムスチン、または薬学的に許容できるその塩と、非水性溶剤とを含んでなる液体医薬製剤を提供するステップと;
前記液体医薬製剤を薬学的に許容できる注射用希釈剤で希釈するステップ
を含んでなる、ベンダムスチン、または薬学的に許容できるその塩の注射用製剤を調製する方法。 - 前記非水性溶剤が極性非プロトン性溶剤である、請求項50に記載の方法。
- 前記極性非プロトン性溶剤が、1−メチル−2−ピロリドン、1,3−ジメチル−2−イミダゾリジノン、ジメチルアセトアミド、ジメチルスルホキシド、アセトン、テトラヒドロフラン、1,4−ジオキサン、アセトニトリル、ジメチルホルムアミド、炭酸プロピレン、またはそれらの混合物である、請求項51に記載の方法。
- 前記液体医薬製剤が非水性極性プロトン性溶剤をさらに含んでなる、請求項50に記載の方法。
- 前記非水性極性プロトン性溶剤が、アルコール、ポリアルキレングリコール、一級アミド、またはそれらの混合物である、請求項53に記載の方法。
- 前記薬学的に許容できる注射用希釈剤が塩化ナトリウム注射剤である、請求項50に記載の方法。
- 癌治療を必要とする患者を同定するステップと;
治療的に有効量のベンダムスチン、または薬学的に許容できるその塩と、非水性溶剤とを含んでなる液体医薬製剤を提供するステップと;
前記液体医薬製剤を薬学的に許容できる注射用希釈剤で希釈して医薬品を形成するステップと;
前記医薬品を治療を必要とする前記患者に投与するステップと
を含んでなる癌を治療する方法。 - 前記癌が、慢性リンパ球性白血病、ホジキン病、非ホジキンリンパ腫、多発性骨髄腫、または乳癌である、請求項56に記載の方法。
- 前記非水性溶剤が極性非プロトン性溶剤である、請求項56に記載の方法。
- 前記極性非プロトン性溶剤が、1−メチル−2−ピロリドン、1,3−ジメチル−2−イミダゾリジノン、ジメチルアセトアミド、ジメチルスルホキシド、アセトン、テトラヒドロフラン、1,4−ジオキサン、アセトニトリル、ジメチルホルムアミド、炭酸プロピレン、またはそれらの混合物である、請求項58に記載の方法。
- 前記液体医薬製剤が非水性極性プロトン性溶剤をさらに含んでなる、請求項56に記載の方法。
- 前記非水性極性プロトン性溶剤がアルコール、ポリアルキレングリコール、一級アミド、またはそれらの混合物である、請求項60に記載の方法。
- 前記薬学的に許容できる注射用希釈剤が塩化ナトリウム注射剤である、請求項56に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10007408P | 2008-09-25 | 2008-09-25 | |
US61/100,074 | 2008-09-25 | ||
PCT/US2009/058023 WO2010036702A1 (en) | 2008-09-25 | 2009-09-23 | Liquid formulations of bendamustine |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012503666A true JP2012503666A (ja) | 2012-02-09 |
JP2012503666A5 JP2012503666A5 (ja) | 2012-11-08 |
JP5670335B2 JP5670335B2 (ja) | 2015-02-18 |
Family
ID=41559533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011529180A Active JP5670335B2 (ja) | 2008-09-25 | 2009-09-23 | ベンダムスチン液体製剤 |
Country Status (9)
Country | Link |
---|---|
US (10) | US20110190363A1 (ja) |
EP (2) | EP2326306A1 (ja) |
JP (1) | JP5670335B2 (ja) |
CN (2) | CN104224703A (ja) |
AU (5) | AU2009296734B2 (ja) |
CA (1) | CA2735899A1 (ja) |
HK (1) | HK1211462A1 (ja) |
MX (1) | MX2011002936A (ja) |
WO (1) | WO2010036702A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013518130A (ja) * | 2010-01-28 | 2013-05-20 | イーグル・ファーマシューティカルズ・インコーポレーテッド | ベンダムスチンの製剤 |
JP2015506989A (ja) * | 2012-02-14 | 2015-03-05 | イーグル・ファーマシューティカルズ・インコーポレーテッド | ベンダムスチン製剤 |
JP2015536996A (ja) * | 2012-11-12 | 2015-12-24 | イグニタ、インク. | ベンダムスチン誘導体およびこれを使用する方法 |
JP2016531138A (ja) * | 2013-08-27 | 2016-10-06 | ボウドウリス バシリオス | ベンダムスチンの薬学的組成物 |
US9572888B2 (en) | 2012-03-20 | 2017-02-21 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
US9579384B2 (en) | 2012-03-20 | 2017-02-28 | Eagle Pharmaceuticals, Inc. | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration |
JP2019526572A (ja) * | 2016-08-31 | 2019-09-19 | ナビンタ エルエルシー | ベンダムスチン溶液製剤 |
JP2020109066A (ja) * | 2019-01-07 | 2020-07-16 | コーアイセイ株式会社 | ベンダムスチンの液体製剤 |
JP2021519817A (ja) * | 2018-03-29 | 2021-08-12 | プロジェクト ファーマシューティクス ゲーエムベーハー | 液体薬学的製剤 |
Families Citing this family (159)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005099724A2 (en) * | 2004-04-13 | 2005-10-27 | Parallel Solutions, Inc. | Functionalized water-soluble polyphosphazene and uses thereof as modifiers of biological agents |
US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
WO2006036969A2 (en) | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Formation of barrier layer |
US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
US11266607B2 (en) * | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
US20070086958A1 (en) * | 2005-10-14 | 2007-04-19 | Medafor, Incorporated | Formation of medically useful gels comprising microporous particles and methods of use |
CN101686641B (zh) * | 2007-02-05 | 2014-05-07 | 新加坡国立大学 | 推定的细胞激动素受体和其应用方法 |
US8097712B2 (en) | 2007-11-07 | 2012-01-17 | Beelogics Inc. | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
CA2735899A1 (en) | 2008-09-25 | 2010-04-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
KR101355695B1 (ko) * | 2009-02-06 | 2014-01-27 | 더 프록터 앤드 갬블 캄파니 | 붕괴성 수분-함유 캡슐 |
CN102458112A (zh) * | 2009-04-10 | 2012-05-16 | 阿布拉科斯生物科学有限公司 | 纳米颗粒制剂及其用途 |
JP5858906B2 (ja) | 2009-05-04 | 2016-02-10 | シヴィダ・ユーエス・インコーポレイテッドPsivida Us, Inc. | 多孔質シリコン薬物溶出粒子 |
WO2010144675A1 (en) | 2009-06-10 | 2010-12-16 | Plus Chemicals Sa | Polymorphs of bendamustine hcl and processes for preparation thereof |
US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
CN102770113A (zh) * | 2009-12-29 | 2012-11-07 | 格雷斯公司 | 形成具有所需遮蔽度的膜的组合物及其制造和使用方法 |
MX351010B (es) * | 2010-02-04 | 2017-09-28 | Isp Investments Inc | Polimeros autoadaptables para formulaciones de filtro solar, anhidras. |
WO2011103150A2 (en) * | 2010-02-18 | 2011-08-25 | Cephalon, Inc. | Lyophilized preparations of bendamustine |
MX2012009634A (es) * | 2010-02-18 | 2012-09-28 | Athenix Corp | Genes delta-endotoxinicos axmi218, axmi219, axmi220, axmi226, axmi227, axmi228, axmi229, axmi230, y axmi231 y metodos para sus uso. |
BR112012020705B8 (pt) | 2010-02-18 | 2022-07-05 | Athenix Corp | Molécula de ácido nucleico recombinante, vetor, célula hospedeira microbiana, polipeptídeo recombinante com atividade pesticida, composição, bem como métodos para o controle de uma população de pragas de lepidópteros, para matar uma praga de lepidóptero, para a produção de um polipeptídeo com atividade pesticida, para a proteção de uma planta de uma praga, e para aumentar o rendimento em uma planta |
CA2790211C (en) | 2010-03-08 | 2020-06-09 | Monsanto Technology Llc | Methods and compositions for delivering polynucleotides into plants |
FR2958155B1 (fr) * | 2010-04-02 | 2012-04-20 | Oreal | Composition de decoloration comprenant un sel peroxygene dans une base fortement riche en corps gras |
WO2011137563A1 (en) * | 2010-05-07 | 2011-11-10 | Unilever Plc | High solvent content emulsions |
NZ603506A (en) | 2010-06-04 | 2013-11-29 | Monsanto Technology Llc | Transgenic brassica event mon 88302 and methods of use thereof |
US9724329B2 (en) * | 2010-06-21 | 2017-08-08 | Peter Maccallum Cancer Institute | Stimulating immune response |
US10322213B2 (en) | 2010-07-16 | 2019-06-18 | Atrium Medical Corporation | Compositions and methods for altering the rate of hydrolysis of cured oil-based materials |
US8383663B2 (en) * | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
US8802933B2 (en) * | 2010-08-19 | 2014-08-12 | Pioneer Hi Bred International Inc | Bacillus thuringiensis gene with lepidopteran activity |
ES2675913T3 (es) * | 2010-10-28 | 2018-07-13 | Aequus Pharmaceuticals Inc. | Composiciones de aripiprazol y métodos para su administración transdérmica |
US9757374B2 (en) | 2010-10-28 | 2017-09-12 | Aequus Pharmaceuticals Inc. | Aripiprazole compositions and methods for its transdermal delivery |
CN104586742A (zh) | 2010-11-01 | 2015-05-06 | 普西维达公司 | 用于递送治疗剂的可生物侵蚀的硅基装置 |
JP6063877B2 (ja) | 2011-03-10 | 2017-01-18 | ゼリス ファーマシューティカルズ インコーポレイテッド | ペプチド薬物の非経口注射用の安定な製剤 |
WO2012170355A2 (en) * | 2011-06-04 | 2012-12-13 | The Texas A&M University System | Potato transformation compositions, systems, methods, microorganisms, and plants |
JP2013032332A (ja) * | 2011-07-01 | 2013-02-14 | Lintec Corp | 免疫賦活剤 |
EP2742059A1 (en) * | 2011-08-12 | 2014-06-18 | Bayer CropScience NV | Guard cell-specific expression of transgenes in cotton |
US9840715B1 (en) | 2011-09-13 | 2017-12-12 | Monsanto Technology Llc | Methods and compositions for delaying senescence and improving disease tolerance and yield in plants |
US10806146B2 (en) | 2011-09-13 | 2020-10-20 | Monsanto Technology Llc | Methods and compositions for weed control |
US10760086B2 (en) | 2011-09-13 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for weed control |
EP2755467B1 (en) | 2011-09-13 | 2017-07-19 | Monsanto Technology LLC | Methods and compositions for weed control |
MX343072B (es) | 2011-09-13 | 2016-10-21 | Monsanto Technology Llc | Metodos y composiciones para controlar malezas. |
US10829828B2 (en) | 2011-09-13 | 2020-11-10 | Monsanto Technology Llc | Methods and compositions for weed control |
MX343071B (es) | 2011-09-13 | 2016-10-21 | Monsanto Technology Llc | Metodos y composiciones para el control de malezas. |
BR112014005975A8 (pt) | 2011-09-13 | 2017-09-12 | Monsanto Technology Llc | Método de controle de planta, método de redução de expressão de um gene pds em uma planta, cassete de expressão microbiana, método de fazer um polinucleotídeo, método de identificação de polinucleotídeos, e composições para controle de erva daninha |
US9920326B1 (en) | 2011-09-14 | 2018-03-20 | Monsanto Technology Llc | Methods and compositions for increasing invertase activity in plants |
MX346432B (es) * | 2011-09-18 | 2017-03-21 | Euro-Celtique S A * | Composiciones farmaceuticas. |
ES2613838T3 (es) | 2011-09-26 | 2017-05-26 | Fresenius Kabi Oncology Ltd | Un procedimiento mejorado para la preparación de hidrocloruro de bendamustina |
EP2764046B1 (en) * | 2011-10-05 | 2021-04-21 | DuPont Nutrition USA, Inc. | Stabilizer composition of microcrystalline cellulose and carboxymethylcellulose, method for making, and uses |
US9492363B1 (en) * | 2012-01-16 | 2016-11-15 | American Spraytech, L.L.C. | Aerosol sprayable color composition |
US20130210878A1 (en) * | 2012-01-24 | 2013-08-15 | Innopharma, Inc. | Bendamustine compositions and methods therefore |
NZ627242A (en) * | 2012-01-27 | 2016-08-26 | Agile Therapeutics Inc | Transdermal hormone delivery |
TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
WO2013148919A1 (en) | 2012-03-30 | 2013-10-03 | The Regents Of The University Of Colorado, A Body Corporate | Treatment of multiple myeloma |
AU2013264742B2 (en) | 2012-05-24 | 2018-10-04 | A.B. Seeds Ltd. | Compositions and methods for silencing gene expression |
US9125805B2 (en) * | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
US20230241218A1 (en) * | 2012-07-10 | 2023-08-03 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
CN109260455A (zh) * | 2012-08-03 | 2019-01-25 | Msm创新有限公司 | 矫味试剂盒 |
US10323279B2 (en) | 2012-08-14 | 2019-06-18 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US20150376609A1 (en) | 2014-06-26 | 2015-12-31 | 10X Genomics, Inc. | Methods of Analyzing Nucleic Acids from Individual Cells or Cell Populations |
US9701998B2 (en) | 2012-12-14 | 2017-07-11 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10273541B2 (en) | 2012-08-14 | 2019-04-30 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10400280B2 (en) | 2012-08-14 | 2019-09-03 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10752949B2 (en) | 2012-08-14 | 2020-08-25 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US9951386B2 (en) | 2014-06-26 | 2018-04-24 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
MX364957B (es) | 2012-08-14 | 2019-05-15 | 10X Genomics Inc | Composiciones y metodos para microcapsulas. |
US10221442B2 (en) | 2012-08-14 | 2019-03-05 | 10X Genomics, Inc. | Compositions and methods for sample processing |
US11591637B2 (en) | 2012-08-14 | 2023-02-28 | 10X Genomics, Inc. | Compositions and methods for sample processing |
US9801859B2 (en) | 2012-09-18 | 2017-10-31 | Innopharma Licensing, Llc | Bendamustine formulations |
US9617297B2 (en) * | 2012-10-11 | 2017-04-11 | The Regents Of The University Of California | Apoplast wash fluid recovery for improved recombinant endoglucanase extraction in tabacco leaves |
CN104870647A (zh) | 2012-10-18 | 2015-08-26 | 孟山都技术公司 | 用于植物害虫控制的方法和组合物 |
EP2732811B1 (de) * | 2012-11-19 | 2016-01-13 | Oncotec Pharma Produktion GmbH | Verfahren zur Herstellung einer gefriergetrockneten Zusammensetzung |
US10533221B2 (en) | 2012-12-14 | 2020-01-14 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
CA2894694C (en) | 2012-12-14 | 2023-04-25 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US9206436B2 (en) * | 2012-12-20 | 2015-12-08 | Ut-Battelle, Llc | Key gene regulating cell wall biosynthesis and recalcitrance in Populus, gene Y |
WO2014106837A2 (en) | 2013-01-01 | 2014-07-10 | A. B. Seeds Ltd. | ISOLATED dsRNA MOLECULES AND METHODS OF USING SAME FOR SILENCING TARGET MOLECULES OF INTEREST |
US10683505B2 (en) | 2013-01-01 | 2020-06-16 | Monsanto Technology Llc | Methods of introducing dsRNA to plant seeds for modulating gene expression |
US10000767B2 (en) | 2013-01-28 | 2018-06-19 | Monsanto Technology Llc | Methods and compositions for plant pest control |
US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
CA2900481A1 (en) | 2013-02-08 | 2014-08-14 | 10X Genomics, Inc. | Polynucleotide barcode generation |
US8961680B2 (en) * | 2013-03-08 | 2015-02-24 | Tbf Environmental Technology Inc. | Solvent formulations |
US20140271764A1 (en) * | 2013-03-12 | 2014-09-18 | Psivida Us, Inc. | Bioerodible Silicon-Based Delivery Vehicles for Delivery of Therapeutic Agents |
AR095233A1 (es) | 2013-03-13 | 2015-09-30 | Monsanto Technology Llc | Métodos y composiciones para el control de malezas |
CA2905027A1 (en) | 2013-03-13 | 2014-10-09 | Monsanto Technology Llc | Methods and compositions for weed control |
US20140283211A1 (en) | 2013-03-14 | 2014-09-18 | Monsanto Technology Llc | Methods and Compositions for Plant Pest Control |
EP2968571A4 (en) | 2013-03-15 | 2016-09-07 | Psivida Inc | BIODEGRADABLE SILICONE BASED COMPOSITIONS FOR THE DELIVERY OF THERAPEUTIC AGENTS |
US10568328B2 (en) | 2013-03-15 | 2020-02-25 | Monsanto Technology Llc | Methods and compositions for weed control |
DK2968099T3 (da) * | 2013-03-15 | 2020-07-20 | Maria Beug Deeb Inc Dba T&M Ass | Metoder og sammensætninger til rengøring og desinfektion af overflader |
CA2817728A1 (en) * | 2013-05-31 | 2014-11-30 | Pharmascience Inc. | Abuse deterrent immediate release formulation |
US9850496B2 (en) | 2013-07-19 | 2017-12-26 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
EP3030663B1 (en) | 2013-07-19 | 2019-09-04 | Monsanto Technology LLC | Compositions and methods for controlling leptinotarsa |
CN103351347A (zh) * | 2013-07-29 | 2013-10-16 | 东南大学 | 盐酸苯达莫司汀杂质dce的制备方法 |
ES2693580T3 (es) * | 2013-10-07 | 2018-12-12 | Bristol-Myers Squibb Holdings Ireland | Formulación de tratamiento del VIH de atazanavir y cobicistat |
WO2015054550A1 (en) * | 2013-10-11 | 2015-04-16 | Luitpold Pharmaceuticals, Inc. | Bendamustine pharmaceutical compositions |
US9540642B2 (en) | 2013-11-04 | 2017-01-10 | The United States Of America, As Represented By The Secretary Of Agriculture | Compositions and methods for controlling arthropod parasite and pest infestations |
UA119253C2 (uk) | 2013-12-10 | 2019-05-27 | Біолоджикс, Інк. | Спосіб боротьби із вірусом у кліща varroa та у бджіл |
IN2014CH00151A (ja) * | 2014-01-13 | 2015-07-17 | Hetero Research Foundation | |
AU2015206585A1 (en) | 2014-01-15 | 2016-07-21 | Monsanto Technology Llc | Methods and compositions for weed control using EPSPS polynucleotides |
AU2015229842B2 (en) * | 2014-03-13 | 2020-06-25 | Vasilios VOUDOURIS | Bendamustine solid dispersions and continuous infusion |
EP3420809A1 (en) | 2014-04-01 | 2019-01-02 | Monsanto Technology LLC | Compositions and methods for controlling insect pests |
AU2015243445B2 (en) | 2014-04-10 | 2020-05-28 | 10X Genomics, Inc. | Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same |
GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
WO2015200223A1 (en) | 2014-06-23 | 2015-12-30 | Monsanto Technology Llc | Compositions and methods for regulating gene expression via rna interference |
EP3161138A4 (en) | 2014-06-25 | 2017-12-06 | Monsanto Technology LLC | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
EP3167049A4 (en) | 2014-07-08 | 2017-11-29 | MIMEDX Group Inc. | Micronized wharton's jelly |
US20160022604A1 (en) * | 2014-07-23 | 2016-01-28 | Cadila Healthcare Limited | Directly compressed ospemifene compositions |
WO2016018887A1 (en) | 2014-07-29 | 2016-02-04 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
CA2957399C (en) | 2014-08-06 | 2023-09-26 | Xeris Pharmaceuticals, Inc. | Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes |
KR102305346B1 (ko) * | 2014-09-11 | 2021-09-28 | 겔리타 아게 | 젤라틴/펙틴 입자 |
BR112017005505B1 (pt) | 2014-09-17 | 2022-09-06 | Arxada, LLC | Composição de peróxido de hidrogênio de solução desinfetante pronta para uso |
US20160122817A1 (en) | 2014-10-29 | 2016-05-05 | 10X Genomics, Inc. | Methods and compositions for targeted nucleic acid sequencing |
US9975122B2 (en) | 2014-11-05 | 2018-05-22 | 10X Genomics, Inc. | Instrument systems for integrated sample processing |
US9603930B2 (en) * | 2014-12-04 | 2017-03-28 | Navinta, Llc | Liquid bendamustine formulation |
JP6706827B2 (ja) * | 2015-01-06 | 2020-06-10 | 山田 修 | 燃焼合成材料を利用した医薬組成物、血液処理装置、化粧料及び飲食品 |
SG11201705615UA (en) | 2015-01-12 | 2017-08-30 | 10X Genomics Inc | Processes and systems for preparing nucleic acid sequencing libraries and libraries prepared using same |
US10968449B2 (en) | 2015-01-22 | 2021-04-06 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
EP3262407B1 (en) | 2015-02-24 | 2023-08-30 | 10X Genomics, Inc. | Partition processing methods and systems |
EP3262188B1 (en) | 2015-02-24 | 2021-05-05 | 10X Genomics, Inc. | Methods for targeted nucleic acid sequence coverage |
WO2016137804A1 (en) | 2015-02-25 | 2016-09-01 | The Procter & Gamble Company | Fibrous structures comprising a surface softening composition |
US20160303043A1 (en) * | 2015-04-16 | 2016-10-20 | Kate Somerville Skincare, LLC | Self-foaming compositions and methods |
UY36703A (es) | 2015-06-02 | 2016-12-30 | Monsanto Technology Llc | Composiciones y métodos para la administración de un polinucleótido en una planta |
EP3302030A4 (en) | 2015-06-03 | 2019-04-24 | Monsanto Technology LLC | METHODS AND COMPOSITIONS FOR THE INTRODUCTION OF NUCLEIC ACIDS IN PLANTS |
US9649364B2 (en) | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
MX2018000351A (es) | 2015-07-10 | 2018-11-12 | Procter & Gamble | Composición para el cuidado de telas que comprende poliolésteres insaturados metatesizados. |
US11590205B2 (en) | 2015-09-25 | 2023-02-28 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
SG11201804086VA (en) | 2015-12-04 | 2018-06-28 | 10X Genomics Inc | Methods and compositions for nucleic acid analysis |
CN110772480B (zh) * | 2016-03-25 | 2022-05-17 | 南京百劲企业管理咨询有限公司 | 苯达莫司汀药剂组合物及应用 |
WO2017197338A1 (en) | 2016-05-13 | 2017-11-16 | 10X Genomics, Inc. | Microfluidic systems and methods of use |
EP3481366B1 (en) * | 2016-07-08 | 2022-07-27 | The Gillette Company LLC | Liquid compositions for hair removal devices comprising metathesized unsaturated polyol esters |
US11826466B2 (en) | 2016-08-31 | 2023-11-28 | Navinta, Llc | Bendamustine solution formulations |
WO2018068832A1 (en) | 2016-10-11 | 2018-04-19 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
DE102016223333A1 (de) * | 2016-11-24 | 2018-05-24 | Henkel Ag & Co. Kgaa | Alkalische Mittel zum Aufhellen von Haaren enthaltend Oxidationsmittel und spezielle Carbonsäureester als Keratinvernetzer |
US10011872B1 (en) | 2016-12-22 | 2018-07-03 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10815525B2 (en) | 2016-12-22 | 2020-10-27 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10550429B2 (en) | 2016-12-22 | 2020-02-04 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
EP4029939B1 (en) | 2017-01-30 | 2023-06-28 | 10X Genomics, Inc. | Methods and systems for droplet-based single cell barcoding |
WO2018160882A1 (en) | 2017-03-01 | 2018-09-07 | Arena Pharmaceuticals, Inc. | Compositions comprising pgi2-receptor agonists and processes for the preparation thereof |
US10398670B2 (en) * | 2017-04-24 | 2019-09-03 | Knoze Jr. Corporation | Oral microbiota promotion for oral and/or sinus infections |
CN116064732A (zh) | 2017-05-26 | 2023-05-05 | 10X基因组学有限公司 | 转座酶可接近性染色质的单细胞分析 |
US10400235B2 (en) | 2017-05-26 | 2019-09-03 | 10X Genomics, Inc. | Single cell analysis of transposase accessible chromatin |
KR20240036128A (ko) | 2017-06-02 | 2024-03-19 | 엑스에리스 파머수티클스, 인크. | 침전 방지 저분자 약물 제제 |
GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
US10471033B2 (en) * | 2017-09-15 | 2019-11-12 | Knoze Jr. Corporation | Oral microbiota promotion for immune system associated inflammations |
KR102450975B1 (ko) * | 2017-10-05 | 2022-10-07 | 튜브 파마수티칼스 게엠베하 | 경구 벤다무스틴 제형 |
WO2019097413A1 (en) * | 2017-11-15 | 2019-05-23 | Intas Pharmaceuticals Ltd. | Stable non-aqueous pharmaceutical compositions |
SG11201913654QA (en) | 2017-11-15 | 2020-01-30 | 10X Genomics Inc | Functionalized gel beads |
US10829815B2 (en) | 2017-11-17 | 2020-11-10 | 10X Genomics, Inc. | Methods and systems for associating physical and genetic properties of biological particles |
SG11202009889VA (en) | 2018-04-06 | 2020-11-27 | 10X Genomics Inc | Systems and methods for quality control in single cell processing |
CA3108321A1 (en) * | 2018-08-17 | 2020-02-20 | Hospira Australia Pty Ltd | Liquid bendamustine pharmaceutical compositions |
US11730815B2 (en) | 2018-11-26 | 2023-08-22 | Good Health, Llc | Stable liquid pharmaceutical compositions comprising bendamustine |
CN110123747A (zh) * | 2019-04-26 | 2019-08-16 | 嘉兴市爵拓科技有限公司 | 苯达莫司汀的制剂 |
US11707450B1 (en) | 2022-03-03 | 2023-07-25 | Slayback Pharma Llc | Stable pharmaceutical compositions of bendamustine |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD159289A1 (de) * | 1981-06-01 | 1983-03-02 | Uwe Olthoff | Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen |
JPH04506659A (ja) * | 1989-05-09 | 1992-11-19 | ピートロニグロ,デニス・ディ | 抗腫瘍溶液 |
JP2008519047A (ja) * | 2004-11-05 | 2008-06-05 | セフアロン・インコーポレーテツド | 癌処置 |
JP2008526991A (ja) * | 2005-01-14 | 2008-07-24 | セフアロン・インコーポレーテツド | ベンダムスチン製薬学的組成物 |
JP2008533152A (ja) * | 2005-03-14 | 2008-08-21 | ヤウポン セラペウチクス,インク. | 発揮性アルキル化剤の安定化組成物およびその使用方法 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE159289C (ja) | 1903-10-08 | 1905-03-16 | ||
DD159877A1 (de) | 1981-06-12 | 1983-04-13 | Wolfgang Krueger | Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure |
IT1153974B (it) * | 1982-09-23 | 1987-01-21 | Erba Farmitalia | Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento |
DE3446873A1 (de) * | 1984-12-21 | 1986-07-10 | Merckle Gmbh | Fluessige diclofenac-zubereitungen |
US5204335A (en) * | 1986-10-31 | 1993-04-20 | Asta Pharma Aktiengesellschaft | Ifosfamide lyophilisate and process for its preparation |
US5162115A (en) * | 1989-05-09 | 1992-11-10 | Pietronigro Dennis D | Antineoplastic solution and method for treating neoplasms |
DD293808A5 (de) | 1990-04-23 | 1991-09-12 | Zi Fuer Mikrobiologie Uns Experimentelle Therapie,De | Verfahren zur herstellung von (5-[bis(2-chlorethyl)amino]-1-methyl-benzimidazolyl(2)ethansaeurealkylestern |
US5227373A (en) * | 1991-10-23 | 1993-07-13 | Bristol-Myers Squibb Co. | Lyophilized ifosfamide compositions |
PT752248E (pt) * | 1992-11-13 | 2001-01-31 | Idec Pharma Corp | Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b |
US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
ATE187071T1 (de) * | 1993-10-27 | 1999-12-15 | Upjohn Co | Stabilisiertes prostaglandin e1 |
US5561121A (en) | 1993-11-09 | 1996-10-01 | American Cyanamid Company | Stable lyophilized thiotepa composition |
US5955504A (en) | 1995-03-13 | 1999-09-21 | Loma Linda University Medical Center | Colorectal chemoprotective composition and method of preventing colorectal cancer |
DE19529057B4 (de) * | 1995-08-08 | 2007-12-13 | Baxter Healthcare S.A. | Ifosfamid-Lyophilisat-Zubereitungen |
US6261537B1 (en) * | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
US6077850A (en) * | 1997-04-21 | 2000-06-20 | G.D. Searle & Co. | Substituted benzopyran analogs for the treatment of inflammation |
US6034256A (en) * | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
US20040072889A1 (en) * | 1997-04-21 | 2004-04-15 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia |
NZ509376A (en) * | 1998-07-09 | 2003-10-31 | Francis A Nardella | Indole or carbazole derivatives for the treatment of chronic lyphocytic leukemia |
US5972912A (en) * | 1998-12-17 | 1999-10-26 | S.P. Pharmaceuticals | Method for lyophilizing ifosfamide |
US6569402B1 (en) * | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
US6380210B1 (en) * | 1999-04-02 | 2002-04-30 | Neurogen Corporation | Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors |
US6545034B1 (en) * | 1999-07-23 | 2003-04-08 | The Regents Of The University Of California | Use of etodolac for the treatment of chronic lymphocytic leukemia |
DE10016077A1 (de) | 2000-03-31 | 2001-12-13 | Cellcontrol Biomedical Lab Gmb | Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen |
US20040152672A1 (en) * | 2000-08-09 | 2004-08-05 | Carson Dennis A. | Indole compounds useful for the treatment of cancer |
CN1487936A (zh) * | 2000-12-11 | 2004-04-07 | ����ҩƷ��ҵ��ʽ���� | 具有改进吸收性能的药物组合物 |
PL362979A1 (en) * | 2000-12-11 | 2004-11-02 | Takeda Chemical Industries, Ltd. | Medicinal compositions improved in solublity in water |
WO2003034944A1 (de) * | 2001-10-15 | 2003-05-01 | Hemoteq Gmbh | Beschichtung von stents zur verhinderung von restenose |
US6613927B1 (en) | 2002-02-08 | 2003-09-02 | American Pharmaceutical Partners, Inc. | Sterile lyophilized ifosfamide and associated methods |
DE10306724A1 (de) | 2002-02-28 | 2003-09-18 | G O T Therapeutics Gmbh | Vesikuläre Verkapselung von Bendamustin |
ES2303588T3 (es) | 2002-03-22 | 2008-08-16 | Ludwig Maximilians Universitat | Ensayo de citocapacidad. |
EP1354952A1 (en) | 2002-04-17 | 2003-10-22 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Smac-peptides as therapeutics against cancer and autoimmune diseases |
WO2003086470A2 (en) | 2002-04-17 | 2003-10-23 | Deutsches Krebsforschungszentrum | Smac-peptides as therapeutics against cancer and autoimmune diseases |
CN1318103C (zh) | 2002-05-09 | 2007-05-30 | 亨莫特克股份有限公司 | 酰化多糖作为血液相容性涂层用于预防或减轻再狭窄的应用 |
US20040096436A1 (en) * | 2002-08-02 | 2004-05-20 | Regents Of The University Of California | Methods for inhibiting protein kinases in cancer cells |
DE10304403A1 (de) | 2003-01-28 | 2004-08-05 | Röhm GmbH & Co. KG | Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung |
EP1444989A1 (en) | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
US7157551B2 (en) * | 2003-02-14 | 2007-01-02 | Cephalon, Inc. | Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers |
CN1829514A (zh) * | 2003-07-25 | 2006-09-06 | 惠氏公司 | Cci-779冻干制剂 |
UA94036C2 (ru) * | 2005-01-14 | 2011-04-11 | Сефалон, Инк. | Фармацевтическая композиция бендамустина, предназначенная для лиофилизации |
AR072777A1 (es) * | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
CA2735899A1 (en) | 2008-09-25 | 2010-04-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
-
2009
- 2009-09-23 CA CA2735899A patent/CA2735899A1/en not_active Abandoned
- 2009-09-23 EP EP09740213A patent/EP2326306A1/en not_active Withdrawn
- 2009-09-23 JP JP2011529180A patent/JP5670335B2/ja active Active
- 2009-09-23 WO PCT/US2009/058023 patent/WO2010036702A1/en active Application Filing
- 2009-09-23 EP EP15152744.7A patent/EP2889029A1/en not_active Withdrawn
- 2009-09-23 AU AU2009296734A patent/AU2009296734B2/en active Active
- 2009-09-23 MX MX2011002936A patent/MX2011002936A/es active IP Right Grant
- 2009-09-23 CN CN201410449785.0A patent/CN104224703A/zh active Pending
- 2009-09-23 CN CN200980137977.5A patent/CN102164579B/zh active Active
-
2011
- 2011-03-15 US US13/048,325 patent/US20110190363A1/en not_active Abandoned
- 2011-12-01 HK HK15111733.2A patent/HK1211462A1/xx unknown
-
2012
- 2012-01-31 US US13/362,430 patent/US8344006B2/en active Active
- 2012-10-19 US US13/655,498 patent/US20130041004A1/en not_active Abandoned
-
2013
- 2013-11-20 US US14/084,768 patent/US20140080881A1/en not_active Abandoned
-
2014
- 2014-01-09 US US14/151,242 patent/US20140128443A1/en not_active Abandoned
- 2014-03-21 US US14/221,422 patent/US20140206733A1/en not_active Abandoned
-
2015
- 2015-07-31 US US14/814,570 patent/US20150335750A1/en not_active Abandoned
- 2015-07-31 AU AU2015207940A patent/AU2015207940B2/en active Active
-
2016
- 2016-05-18 AU AU2016203246A patent/AU2016203246B2/en active Active
- 2016-10-19 AU AU2016247123A patent/AU2016247123A1/en not_active Abandoned
-
2017
- 2017-08-28 US US15/688,182 patent/US20180125824A1/en not_active Abandoned
-
2018
- 2018-03-23 AU AU2018202107A patent/AU2018202107A1/en not_active Abandoned
-
2020
- 2020-03-31 US US16/835,562 patent/US20210008035A1/en not_active Abandoned
- 2020-09-09 US US17/015,175 patent/US20210113530A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD159289A1 (de) * | 1981-06-01 | 1983-03-02 | Uwe Olthoff | Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen |
JPH04506659A (ja) * | 1989-05-09 | 1992-11-19 | ピートロニグロ,デニス・ディ | 抗腫瘍溶液 |
JP2008519047A (ja) * | 2004-11-05 | 2008-06-05 | セフアロン・インコーポレーテツド | 癌処置 |
JP2008526991A (ja) * | 2005-01-14 | 2008-07-24 | セフアロン・インコーポレーテツド | ベンダムスチン製薬学的組成物 |
JP2008533152A (ja) * | 2005-03-14 | 2008-08-21 | ヤウポン セラペウチクス,インク. | 発揮性アルキル化剤の安定化組成物およびその使用方法 |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013518130A (ja) * | 2010-01-28 | 2013-05-20 | イーグル・ファーマシューティカルズ・インコーポレーテッド | ベンダムスチンの製剤 |
US11872214B2 (en) | 2010-01-28 | 2024-01-16 | Eagle Pharmaceuticals, Inc. | Formulations of Bendamustine |
US11844783B2 (en) | 2010-01-28 | 2023-12-19 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
US9572796B2 (en) | 2010-01-28 | 2017-02-21 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
US11103483B2 (en) | 2010-01-28 | 2021-08-31 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
US10010533B2 (en) | 2010-01-28 | 2018-07-03 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
US9572797B2 (en) | 2010-01-28 | 2017-02-21 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
JP2015506989A (ja) * | 2012-02-14 | 2015-03-05 | イーグル・ファーマシューティカルズ・インコーポレーテッド | ベンダムスチン製剤 |
US9597399B2 (en) | 2012-03-20 | 2017-03-21 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
JP2019214592A (ja) * | 2012-03-20 | 2019-12-19 | イーグル・ファーマシューティカルズ・インコーポレーテッド | ベンダムスチンの製剤 |
US9579384B2 (en) | 2012-03-20 | 2017-02-28 | Eagle Pharmaceuticals, Inc. | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration |
US9597397B2 (en) | 2012-03-20 | 2017-03-21 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
US9572887B2 (en) | 2012-03-20 | 2017-02-21 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
US10052385B2 (en) | 2012-03-20 | 2018-08-21 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
US9572888B2 (en) | 2012-03-20 | 2017-02-21 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
US9597398B2 (en) | 2012-03-20 | 2017-03-21 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
JP2015536996A (ja) * | 2012-11-12 | 2015-12-24 | イグニタ、インク. | ベンダムスチン誘導体およびこれを使用する方法 |
JP2016531138A (ja) * | 2013-08-27 | 2016-10-06 | ボウドウリス バシリオス | ベンダムスチンの薬学的組成物 |
JP2019526572A (ja) * | 2016-08-31 | 2019-09-19 | ナビンタ エルエルシー | ベンダムスチン溶液製剤 |
JP2021519817A (ja) * | 2018-03-29 | 2021-08-12 | プロジェクト ファーマシューティクス ゲーエムベーハー | 液体薬学的製剤 |
JP7464995B2 (ja) | 2018-03-29 | 2024-04-10 | プロジェクト ファーマシューティクス ゲーエムベーハー | 液体薬学的製剤 |
JP2020109066A (ja) * | 2019-01-07 | 2020-07-16 | コーアイセイ株式会社 | ベンダムスチンの液体製剤 |
JP7235288B2 (ja) | 2019-01-07 | 2023-03-08 | コーアイセイ株式会社 | ベンダムスチンの液体製剤 |
Also Published As
Publication number | Publication date |
---|---|
US20130041004A1 (en) | 2013-02-14 |
HK1211462A1 (en) | 2016-05-27 |
EP2326306A1 (en) | 2011-06-01 |
CA2735899A1 (en) | 2010-04-01 |
AU2015207940B2 (en) | 2016-11-10 |
AU2009296734A1 (en) | 2010-04-01 |
US20210113530A1 (en) | 2021-04-22 |
CN102164579B (zh) | 2014-10-15 |
AU2015207940A1 (en) | 2015-08-20 |
JP5670335B2 (ja) | 2015-02-18 |
EP2889029A1 (en) | 2015-07-01 |
US20210008035A1 (en) | 2021-01-14 |
AU2016203246B2 (en) | 2017-09-21 |
AU2016203246A1 (en) | 2016-06-09 |
AU2016247123A1 (en) | 2016-11-03 |
US20180125824A1 (en) | 2018-05-10 |
US20120129904A1 (en) | 2012-05-24 |
US20140080881A1 (en) | 2014-03-20 |
US20150335750A1 (en) | 2015-11-26 |
US20110190363A1 (en) | 2011-08-04 |
US8344006B2 (en) | 2013-01-01 |
AU2009296734B2 (en) | 2016-02-18 |
US20140206733A1 (en) | 2014-07-24 |
US20140128443A1 (en) | 2014-05-08 |
CN104224703A (zh) | 2014-12-24 |
AU2018202107A1 (en) | 2018-04-19 |
WO2010036702A1 (en) | 2010-04-01 |
MX2011002936A (es) | 2011-04-11 |
CN102164579A (zh) | 2011-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210113530A1 (en) | Liquid formulations of bendamustine | |
US9572888B2 (en) | Formulations of bendamustine | |
WO2017175098A1 (en) | Stable liquid pharmaceutical formulations of bendamustine | |
US9801859B2 (en) | Bendamustine formulations | |
WO2016005995A2 (en) | Glycol free stable liquid compositions of bendamustine | |
AU2021256189A1 (en) | Stable ready to dilute formulations of carfilzomib | |
US20150087681A1 (en) | Bendamustine HCL Stable Lyophilized Formulations | |
US20100210681A1 (en) | Aqueous pharmaceutical composition | |
WO2019130228A1 (en) | Stable liquid compositions of melphalan | |
US20190070136A1 (en) | Parenteral compositions of carmustine | |
US11826466B2 (en) | Bendamustine solution formulations | |
WO2014170769A2 (en) | Bendamustine lyophilized pharmaceutical compositions | |
BR102019004382A2 (pt) | Composição estéril injetável | |
US20150297523A1 (en) | Pharmaceutical composition comprising bendamustine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120906 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120906 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120919 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140225 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140523 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140530 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140625 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140812 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141125 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141217 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5670335 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |